Результаты поиска

Immunologic and clinical effects of targeting PD-1 in lung cancer.

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD-1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.

Совпадение в полном тексте источника
… A phase I/II study will evaluate the safety, tolerability, and efficacy of pembrolizumab in different combinations with chemotherapy, targeted agents (bevacizumab, erlotinib, and gefitinib), and ipilimumab ( NCT02039674 ); and a phase I study will study responses and safety of pembrolizumab monotherapy …

Токсичность ингибиторов иммунных контрольно-пропускных пунктов и комбинаций ингибиторов тиросиназы в твердых опухолях: систематический обзор и метаанализ.

НЕЗАВИСИМЫЙ: Сочетание ингибиторов ингибиторов иммунных контрольно-пропускных пунктов (ИКИ) и ингибиторов тирозиновой киназы (ТКИ) может быть связано со значительной токсичностью. Мы провели систематический анализ и метаанализ токсичности комбинированной обработки ИУИ с ТЗИ (ИКИ + ТЗИ) в ходе клинических испытаний с твердыми нарушениями органов. Наша главная цель - изучить частотность оценок 3 - 5 (В тыс.G3-5) Токсичность, связанная с лечением, и наши вторичные параметры включали в себя частоту токсичности в разбивке по типам лечения, типам заболеваний и исследованиям с применением методов обк

Совпадение в полном тексте источника
… Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation . J Thorac Oncol . ( 2019 ) 14 : 553–9 . doi: 10.1016/j.jtho.2018.11.028 30529597 35 Karam JA Msaouel P Matin SF Campbell MT Zurita AJ Shah AY . …

Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.

New cases of invasive cancer in the United States occur among nearly 1.5 million people annually. In 2007, more than 1,500 people died per day with this diagnosis. Cancer is responsible for nearly one in every four deaths reported in the country. Enormous amounts of money and research have been, and are being spent, in an attempt to improve these numbers. While prevention and early detection remain the key to long-term success, treatment in the neo-adjuvant, adjuvant and metastatic settings still centre around two main treatment modalities - radiation therapy and chemotherapy. This article wil

Совпадение в полном тексте источника
… Extra-Cellular Growth Factors Drug | Mechanism of Action | Disease | Toxicity Bevacizumab [ 59 ] | Binds to VEGF | Colon, Lung, Breast cancer | Skin rash Intra-Cellular Tyrosine Kinase Inhibitors Drug | Mechanism of Action | Disease | Toxicity Dasatinib [ 60 ] | Inhibits bcr-abl TK | CML | Fluid retention Gefitinib …

Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.

Mitochondria are key organelles for the maintenance of myocardial tissue homeostasis, playing a pivotal role in adenosine triphosphate (ATP) production, calcium signaling, redox homeostasis, and thermogenesis, as well as in the regulation of crucial pathways involved in cell survival. On this basis, it is not surprising that structural and functional impairments of mitochondria can lead to contractile dysfunction, and have been widely implicated in the onset of diverse cardiovascular diseases, including ischemic cardiomyopathy, heart failure, and stroke. Several studies support mitochondrial t

Совпадение в полном тексте источника
… For instance, the inhibition of EGFR by gefitinib (mainly used for the treatment of non-small cell lung cancer), has been shown to induce mitochondrial membrane potential alteration, cellular plasma membrane permeabilization, and activation of apoptosis in cardiomyocytes [ 174 ]. … EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and in Vitro Rat Studies Chem. Res. Toxicol. 2020 33 1719 1728 10.1021/acs.chemrestox.0c00005 32370496 175. Barton M. Filardo E. Lolait S.J. …

Combination therapy in combating cancer.

Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy. The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a characteristically synergistic or an additive manner. This approach potentially reduces drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumour growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis. The 5-year survival

Совпадение в полном тексте источника
… EGFR, a growth factor receptor that is often regulated through the autocrine growth factor loop in normal bronchial epithelial cells and lung cancer cells [ 120 ], was investigated in a phase II study by Ichihara et al ., where gefitinib in combination with bevacizumab was administered as a potential … serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Circulation 1995 92 790 5 10.1161/01.cir.92.4.790 7641358 139 Ichihara E Hotta K Nogami N Kuyama S Kishino D Fujii M Kozuki T Tabata M Harada D Chikamori K Aoe K Ueoka H Hosokawa S Phase II trial of gefitinib …

KIAA1429-mediated M6A methylation inhibits osteoclast differentiation via stabilizing Lrp4 mRNA and protects against osteoporosis.

N6-methyladenosine (m6A) is a novel epigenetic modification that has been reported to be involved in the progression of osteoporosis (OP), providing new insights into the pathogenesis of OP. The methyltransferases KIAA1429 [also known as virus-like m6A methyltransferase-associated protein (VIRMA)] participates in various essential biological processes by regulating target gene expression levels. However, the function of KIAA1429-mediated m6A modification in OP progression remains unclear. This study aimed to investigate the biological roles and potential underlying mechanisms of KIAA1429 in OP

The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications.

Herbal medicine, particularly in developing regions, remains highly popular due to its cost-effectiveness, accessibility, and minimal risk of adverse effects. Curcuma longa L., commonly known as turmeric, exemplifies such herbal remedies with its extensive history of culinary and medicinal applications across Asia for thousands of years. Traditionally utilized as a dye, flavoring, and in cultural rituals, turmeric has also been employed to treat a spectrum of medical conditions, including inflammatory, bacterial, and fungal infections, jaundice, tumors, and ulcers. Building on this longstandin

Совпадение в полном тексте источника
… This, in turn, resulted in the reversal of gefitinib in non-small cell lung cancer in both in vitro and in vivo conditions. | [ 234 ] 11. | Modulation of enzymes | In vitro and in vivo | Curcumin treatment produces inhibition of NO production, reduced expression of iNOS and COX-2 by inhibiting ERK 1/ …

The role of autophagy in cancer: from molecular mechanism to therapeutic window.

Autophagy is a cellular degradation process that plays a crucial role in maintaining metabolic homeostasis under conditions of stress or nutrient deprivation. This process involves sequestering, breaking down, and recycling intracellular components such as proteins, organelles, and cytoplasmic materials. Autophagy also serves as a mechanism for eliminating pathogens and engulfing apoptotic cells. In the absence of stress, baseline autophagy activity is essential for degrading damaged cellular components and recycling nutrients to maintain cellular vitality. The relationship between autophagy a

Совпадение в полном тексте источника
… Bevacizumab | Adenocarcinoma Rectal Cancer Colon Cancer NCT00909831 | Phase I | HCQ + Temsirolimus | Solid Tumor NCT02257424 | Phase I/II | HCQ+ Trametinib + Dabrafenib | Melanoma NCT01689987 | Phase I | HCQ + Cyclophosphamid + Dexamethasone + Sirolimus | Multiple Myeloma NCT00809237 | Phase I/II | HCQ + Gefitinib …

Functional Investigation of IGF1R Mutations in Multiple Myeloma.

High expression of the receptor tyrosine kinase (RTK) insulin-like growth factor-1 receptor (IGF1R) and RTK mutations are associated with high-risk/worse prognosis in multiple myeloma (MM). Combining the pIGF1R/pINSR inhibitor linsitinib with the proteasome inhibitor (PI) bortezomib seemed promising in a clinical trial, but IGF1R expression was not associated with therapy response. Because the oncogenic impact of IGF1R mutations is so far unknown, we investigated the functional impact of IGF1R mutations on survival signaling, viability/proliferation and survival response to therapy. We transfe

Совпадение в полном тексте источника
… Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 2004 304 1497 1500 10.1126/science.1099314 15118125 52. Morgan G.J. Walker B.A. Davies F.E. The genetic architecture of multiple myeloma Nat. Rev. Cancer 2012 12 335 348 10.1038/nrc3257 22495321 53. …

Bibliometric analysis of bone metastases from lung cancer research from 2004 to 2023.

BackgroundBone metastases of lung cancer (BMLC) severely diminish patients' quality of life due to bone-related events, and the lack of clear guidelines globally regarding medical and surgical treatment significantly reduces patient survival. While knowledge about BMLC has grown exponentially over the past two decades, a comprehensive and objective bibliometric analysis remains absent.MethodsA comprehensive bibliometric analysis was conducted on relevant literature on BMLC extracted from the Web of Science database from 2004 to 2023 by Biblioshiny, VOSviewer, Scimago Graphica, CiteSpace, and M

Совпадение в полном тексте источника
… The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) gefitinib and erlotinib, used in adjuvant chemotherapy, showed significant antitumor activity in lung cancer with EGFR gene mutation ( 39 ). …

Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.

Darwinian clonal evolution provides a necessary framework for understanding tumour progression, yet emerging evidence shows that some cancers depart from a strictly gradualist tempo through episodic "macroevolutionary" leaps. We propose a unifying Burst-Drift-Control (BDC) model in which short-lived genomic reconfigurations ("bursts") that transiently alter heritable genomic states ("reactive heredity") precede longer intervals of constrained expansion, creating time-bounded vulnerabilities that clinicians may strategically steer ("control"). In this usage, the Drift component refers specifica

Совпадение в полном тексте источника
… EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–92. 53. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. …

RNF25 serves as a novel diagnostic and prognostic biomarker in multiple myeloma: a multi-cohort integrative analysis.

BackgroundUbiquitination-related genes (UbRGs) play critical roles in tumor biology. However, their functions in multiple myeloma (MM) remain insufficiently explored.MethodsTranscriptomic data from public databases were integrated to identify UbRGs in MM through WGCNA, differential expression, and protein-protein interaction (PPI) analyses. Functional roles were examined by GO, KEGG, and GSEA, while immune infiltration and drug sensitivity were evaluated using CIBERSORT, ESTIMATE, and OncoPredict. UbRG expression was validated in clinical samples and cell lines by qRT-PCR and western blot, and

Совпадение в полном тексте источника
… RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation. Cell Death Dis. 2018;9(6):587. 10.1038/s41419-018-0651-5. 24. Jezierzanski M, Nafalska N, Stopyra M, Furgol T, Miciak M, Kabut J, et al. …

How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.

Background. Pharmaceutical risk sharing agreements (RSAs) are commonly used to manage uncertainties in costs and/or clinical benefits when new drugs are added to a formulary. However, existing mathematical models of RSAs ignore the impact of RSAs on clinical and financial risk. Methods. We develop a model in which the number of patients, total drug consumption per patient, and incremental health benefits per patient are uncertain at the time of the introduction of a new drug. We use the model to evaluate the impact of six common RSAs on total drug costs and total net monetary benefit (NMB). Re

Совпадение в полном тексте источника
… Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. J Med Econ. 2017;20(1):1–7. 14. Gamba S, Pertile P, Vogler S. The impact of managed entry agreements on pharmaceutical prices. …

Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset.

The goal of this investigation was to identify potential risk factors to predict the onset of medication-related osteonecrosis of the jaw (MRONJ). Through the identification of the multiple variables positively associated to MRONJ, we aim to write a paradigm for integrated MRONJ risk assessment built on the combined analysis of systemic and local risk factors. The characteristics of a cohort of cancer patients treated with zoledronic acid and/or denosumab were investigated; beyond the set of proven risk factors a new potential one, the intake of new molecules for cancer therapy, was addressed.

Совпадение в полном тексте источника
… Degarelix (Firmagon) Abiraterone (Zytiga) Flutamide (Eulexin) Bicalutamide (Casodex) Enzalutamide (Xtandi) Target therapy | Trastuzumab Pertuzumab (Perjeta) Ado-trastuzumab emtansine or T-DM1 (Kadcyla) Lapatinib (Tyverb) Bortezomib (Velcade) Osimertinib (Tagrisso) Erlotinib (Tarceva) Afatinib (Giotrif) Gefitinib …

Clinical guide SEOM on venous thromboembolism in cancer patients.

Venous thromboembolism (VTE) is a common event in cancer patients and one of the major causes of cancer-associated mortality and a leading cause of morbidity. In recent years, the incidence rates of VTE have notably increased; however, VTE is still commonly underestimated by oncologists. VTE is considered an adverse prognostic factor in cancer patients in all settings. In 2011 the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of prophylaxis and treatment of VTE in cancer patients. In an effort to incorporate evidence obtained since the original publication, SE

Совпадение в полном тексте источника
… This thrombotic risk is increased with cetuximab and panitumumab but not with gefitinib and erlotinib. The differences in the results between MoAbs and oral TKIs are still unknown, but the association of cetuximab and panitumumab with other cytotoxic agents probably matters [ 42 ]. …

Mechanisms and Applications of Manganese-Based Nanomaterials in Tumor Diagnosis and Therapy.

Tumors are the second most common cause of mortality globally, ranking just below heart disease. With continuous advances in diagnostic technology and treatment approaches, the survival rates of some cancers have increased. Nevertheless, due to the complexity of the mechanisms underlying tumors, cancer remains a serious public health issue that threatens the health of the population globally. Manganese (Mn) is an essential trace element for the human body. Its regulatory role in tumor biology has received much attention in recent years. Developments in nanotechnology have led to the emergence

Совпадение в полном тексте источника
… After surface hydrophilic modification of MnO 2 nanorods by dopamine hydrochloride, the phospholipid vesicles composed of 1,2-dioleacyl-sn-glycero-3-phosphoethanolamine (DOPE) modified by MnO 2 -PDA enclosed the chemotherapeutic drugs gefitinib (Geb) and bevacizumab (Beb). …

Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation.

Cancer is one of the deadliest non communicable diseases. Numerous anticancer medications have been developed to target the molecular pathways driving cancer. However, there has been no discernible increase in the overall survival rate in cancer patients. Therefore, innovative chemo-preventive techniques and agents are required to supplement standard cancer treatments and boost their efficacy. Fruits and vegetables should be tapped into as a source of compounds that can serve as cancer therapy. Phytochemicals play an important role as sources of new medication in cancer treatment. Some synthet

Совпадение в полном тексте источника
… Taxanes | Cancer Type | Days/Time | Concentration | Effects | References Paclitaxel | triple-negative breast cancer (TNBC) | weekly | 80 (mg/m 2 ) | ↑ stromal tumor-infiltrating lymphocytes and micronucleation | [ 145 ] gefitinib-resistant non-small-cell lung cancer (NSCLC) cells (PC9-MET) | 72 h | 50 …

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics.

Chemotherapy is one of the prime treatment options for cancer. However, the key issues with traditional chemotherapy are recurrence of cancer, development of resistance to chemotherapeutic agents, affordability, late-stage detection, serious health consequences, and inaccessibility. Hence, there is an urgent need to find innovative and cost-effective therapies that can target multiple gene products with minimal adverse reactions. Natural phytochemicals originating from plants constitute a significant proportion of the possible therapeutic agents. In this article, we reviewed the advances and t

Совпадение в полном тексте источника
… Drug tolerance per sisters (DTPs) were formed in EGFR mutant lung cancer cell lines were treated with gefitinib and characterized by increased senescence (CD133 low) and stemness (marked by CD133 high population). … Senescent cells exhibit the SASP (senescence-associated secretory phenotype) phenotype and may connect with other cells through secreted substances that have been SASP treated with gefitinib conditioned medium enhanced CD133 high in CSCs. …

Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways.

Polyphenols constitute an important group of natural products that are traditionally associated with a wide range of bioactivities. These are usually found in low concentrations in natural products and are now available in nutraceuticals or dietary supplements. A group of polyphenols that include apigenin, quercetin, curcumin, resveratrol, EGCG, and kaempferol have been shown to regulate signaling pathways that are central for cancer development, progression, and metastasis. Here, we describe novel mechanistic insights on the effect of this group of polyphenols on key elements of the signaling

Совпадение в полном тексте источника
… In an investigation, it was shown that combining the grape polyphenol resveratrol, quercetin, and catechin at equimolar concentrations inhibits mTOR signaling by means of a dual mechanism of PI3K/Akt and AMPK regulation and potentiates breast cancer to anti-EGFR therapy with Gefitinib, suggesting that …

Bone Effects of Anti-Cancer Treatments in 2024.

Considerable progress has been made in the management of cancer patients in the last decade with the arrival of anti-cancer immunotherapies (immune checkpoint inhibitors) and targeted therapies. As a result, a broad spectrum of cancers, not just hormone-sensitive ones, have seen several patients achieve profound and prolonged remissions, or even cures. The management of medium- and long-term side-effects of treatment and quality of life of patients are essential considerations. This is especially true for bone, as bone fragility can lead to increased fractures and loss of autonomy, ultimately

Совпадение в полном тексте источника
… Acalabrutinib uk OC: inh Afatinib uk OC: inh Alectinib uk uk Alpelisib uk uk Axitinib + (mice) uk Bosutinib uk 0 Brigatinib uk uk Cabozantinib + OC: inh Ceritinib uk uk Cobimetinib uk uk Crizotinib + uk Dabrafenib uk uk Dasatinib + (mice) OC: inh Entrectinib uk uk Erdafitinib uk uk Erlotinib uk OC: inh Gefitinib … | uk Alpelisib | uk | uk Axitinib | + (mice) | uk Bosutinib | uk | 0 Brigatinib | uk | uk Cabozantinib | + | OC: inh Ceritinib | uk | uk Cobimetinib | uk | uk Crizotinib | + | uk Dabrafenib | uk | uk Dasatinib | + (mice) | OC: inh Entrectinib | uk | uk Erdafitinib | uk | uk Erlotinib | uk | OC: inh Gefitinib …